Clinsights uses advanced information systems technology to aggregate population-based clinical outcomes data, and to disseminate this data to device companies and physicians. The company's data collection services include e-registries for clinical research, outcomes databases at key clinical centers, and post-market surveillance studies, and the information is disseminated through specialty websites and Internet-based data systems.Key to Clinsights' approach is building relationships with thought leaders in different clinical specialties, the first of which is interventional cardiology. In this area, Clinsights is working with the Cardiovascular Research Foundation (CRF), sponsors of the leading interventional cardiology conference, the Transcatheter Cardiovascular Therapeutics (TCT) meeting. This partnership has produced Clinsights' first website, TCTMD.com.Clinsights' bet is that it can convince medical device companies of the value of its services, built around the ability to collect and disseminate information, and enhanced by partnerships with leading physicians, in providing a competitive advantage that can help differentiate products and technologies.
by Stephen Levin
Product development and innovation in the medical device industry used to be a somewhat haphazard, off-hand process. It was not...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
